Depression, apathy, anhedonia, and fatigue in Parkinson's disease

Neuropsychiatric Symptoms of Movement Disorders

Volumn , Issue , 2015, Pages 1-28

  Amboni, Marianna ^a,b   Santangelo, Gabriella ^c   Barone, Paolo ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b Department of NeurosciencesReproductive and Odontostomatologic Sciences   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84945405035     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-09537-0_1     Document Type: Chapter

References (193)

1. Kuhn W, Heye N, Muller T. H., et al. The motor performance test series in Parkinson’s disease is influenced by depression. J Neural Transm. 1996;103:349–354.
2. Weintraub D, Moberg P. J., Duda J. E., Katz I. R., Stern M. B. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Ger Soc. 2004; 52:784–788.
3. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000; 69:308–312.
4. Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international study. Mov Disord. 2002; 17:60–67.
5. Leentjens A. F. Depression in Parkinson’s disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol. 2004; 17:120–126.
6. Kummer A, Cardoso F, Teixeira A. L. Suicidal ideation in Parkinson’s disease. CNS Spectr. 2009; 14:431–436.
7. Marsh L, McDonald W. M., Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord. 2006; 21:148–158.
8. Starkstein S. E., Merello M, Jorge R, Brockman S, Bruce D, Petracca G, Robinson R. G. A validation study of depressive syndromes in Parkinson’s disease. Mov Disord. 2008; 23:538–546.
9. Chen J. J., Marsh L. Depression in Parkinson’s disease: identification and management. Pharmacotherapy. 2013; 33:972–983.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorder. 4th ed. Washington: American Psychiatry Association; 1994.
11. Leentjens A. F., Van den Akker M, Metsemakers J. F., Lousberg R, Verhey F. R. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord. 2003; 18:414–418.
12. Ehmann T. S., Beninger R. J., Gawel M. J., Riopelle R. J. Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol. 1990; 3:3–9.
13. Brooks D. J., Piccini P. Imaging in Parkinson’s disease: the role of monoamines in behavior. Biol Psychiatry. 2006; 59:908–918.
14. Eskow Jaunarajs K. L., Angoa-Perez M, Kuhn D. M., Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson’s disease: consequences of L-DOPA treatment. Neurosci Biobehav Rev. 2011;35:556–564.
15. Hesse S, Meyer P. M., Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36:428–435.
16. Weintraub D, Newberg A. B., Cary M. S., Siderowf A. D., Moberg P. J, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227–232.
17. Felicio A. C., Moriyama T. S., Godeiro-Junior C, Shih M. C., Hoexter M Q., Borges V, et al. Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology (Berl). 2010;211:27–31.
18. Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, Volterrani D, Bonuccelli U. Mild affective symptoms in de novo Parkinson’s disease patients: relationship with dopaminergic dysfunction. Eur J Neurol. 2013;20:480–485.
19. Koerts J, Leenders K. L., Koning M, Portman A. T., van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci. 2007;25:3132–136.
20. Politis M, Wu K, Loane C, Turkheimer F. E., Molloy S, Brooks D. J., et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920–1927.
21. Walter U, Hoeppner J, Prudente-Morrissey L, et al. Parkinson’s disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain. 2007;130:1799–1807.
22. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314–1322.
23. Frisina P. G., Haroutunian V, Libow L. S. The neuropathological basis for depression in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:144–148.
24. Mayberg H. S., Starkstein S. E., Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol. 1990;28:57–64.
25. Ring H. A., Bench C. J., Trimble M. R., et al. Depression in Parkinson’s disease. A positron emission study. Br J Psychiatry. 1994;165:333–339.
26. Cardoso E. F., Maia F. M., Fregni F, et al. Depression in Parkinson’s disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. Neuroimage. 2009;47:467–472.
27. Matsui H, Nishinaka K, Oda M, et al. Minor depression and brain perfusion images in Parkinson’s disease. Mov Disord. 2006;21:1169–1174.
28. Feldmann A, Illes Z, Kosztolanyi P, et al. Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord. 2008;23:42–46.
29. Kostic V. S., Agosta F, Petrovic I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010;75:857–863.
30. Luo C, Chen Q, Song W, Chen K, Guo X, Yang J, Huang X, Gong Q, Shang H. F. Resting-state fMRI study on drug-naïve patients with Parkinson’s disease and with depression. J Neurol Neurosurg Psychiatry. 2013;260(11):2754–2760.
31. Santamaria J, Tolosa E, Valles A. Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology. 1986;36:1130–1133.
32. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand. 2006;113:211–220.
33. Lieberman A. Depression in Parkinson’s disease-a review. Acta Neurol Scand. 2006;113:1–8.
34. Shen C. C., Tsai S. J., Perng C. L., Kuo B. I., Yang A. C. Risk of Parkinson disease after depression: a nationwide population-based study. Neurology. 2013;81:1538–1544.
35. Reijnders J. S., Ehrt U, Weber W. E., et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23:183–189.
36. Barone P, et al. Depression and antidepressant use in Parkinson’s disease: results from the PRODEST-PD study. Abstract P1122 poster presented at 11th Congress of EFNS, Brussels. 26 Aug 2007.
37. Farabaugh A. H., Locascio J. J., Yap L, Weintraub D, McDonald W. M., Agoston M, Alpert J. E., Growdon J, Fava M. Pattern of depressive symptoms in Parkinson’s disease. Psychosomatics. 2009;50:448–454.
38. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol. 2010;257:1073–1082.
39. Inoue T, Kitagawa M, Tanaka T, Nakagawa S, Koyama T. Depression and major depressive disorder in patients with Parkinson’s disease. Mov Disord. 2010;25:44–49.
40. Nègre-Pagès L., Grandjean H., Lapeyre-Mestre M., Montastruc J. L., Fourrier A., Lépine J. P., Rascol O., DoPaMiP Study Group. Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPaMiP study. Mov Disord. 2010;25:157–166.
41. van der Hoek T. C., Bus B. A., Matui P, van der Marck M. A., Esselink R. A., Tendolkar I. Prevalence of depression in Parkinson’s disease: effects of disease stage, motor subtype and gender. J Neurol Sci. 2011;310:220–224.
42. Yamanishi T, Tachibana H, Oguru M, Matsui K, Toda K, Okuda B, Oka N. Anxiety and depression in patients with Parkinson’s disease. Intern Med. 2013;52:539–545.
43. Weerkamp N. J., Tissingh G, Poels P. J., Zuidema S. U., Munneke M, Koopmans R. T., Bloem B. R. Nonmotor symptoms in nursing home residents with Parkinson’s disease: prevalence and effect on quality of life. J Am Geriatr Soc. 2013;61:1714–1721.
44. Starkstein S. E., Preziosi T. J., Berthier M. L., Bolduc P. L., Mayberg H. S., Robinson R. G. Depression and cognitive impairment in Parkinson’s disease. Brain. 1989;112:1141–1153.
45. Dissanayaka N. N. W., Sellbach A, Silburn P. A., O’Sullivan J. D., Marsh R, Mellick G. D. Factors associated with depression in Parkinson’s disease. J Affect Disord. 2011;132:82–88.
46. Becker C, Brobert G. P., Johansson S, Jick S. S., Meier C. R. Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol. 2011;18:448–453.
47. Gallagher D. A., Schrag A. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis. 2012;46:581–589.
48. Riedel O, Heuser I, Klotsche J, Dodel R, Wittchen H. U., GEPAD Study Group. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study. J Geriatr Psychiatry Neurol. 2010;23:27–34.
49. Riedel O, Dodel R, Deuschl G, Klotsche J, Förstl H, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Wittchen H. U. Depression and care-dependency in Parkinson’s disease: results from a nationwide study of 1,449 outpatients. Parkinsonism Relat Disord. 2012;18:598–601.
50. Leentjens A. F., Moonen A. J., Dujardin K, Marsh L, Martinez-Martin P, Richard I. H., Starkstein S. E., Köhler S. Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors. Neurology. 2013;81:1036–1043.
51. Williams J. R., Hirsch E. S., Anderson K, Bush A. L., Goldstein S. R., Grill S, Lehmann S, Little J. T., Margolis R. L., Palanci J, Pontone G, Weiss H, Rabins P, Marsh L. A comparison of nine scales to detect depression in Parkinson disease: which scale to use? Neurology. 2012;78:998–1006.
52. Starkstein S. E., Merello M. The unified Parkinson’s disease rating scale: validation study of the mentation, behavior, and mood section. Mov Disord. 2007;22:2156–2161.
53. Hamilton M. Å rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
54. Montgomery S. A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
55. Leentjens A. F., Verhey F. R., Lousberg R, Spitsbergen H, Wilmink F. W. The validity of the Hamilton and Montgomery-Åsberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2000;15:644–649.
56. Kroenke K, Spitzer R. L., Williams J. B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613.
57. Leentjens A. F., Verhey F. R. J., Luijckx G. J., Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov Disord. 2000;15:1221–1224.
58. Naarding P, Leentjens A. F. G., van Kooten F, Verhey F. R. J. Disease-specific properties of the Hamilton Rating Scale for depression in patients with stroke, Alzheimer’s disease, and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2002;14:329–348.
59. Mc Donald W. M., Holtzheimer P. E., Haber M, Vitek J. L, McWhorter K, Delong M. Validity of the 30-item geriatric depression scale in patients with Parkinson’s disease. Mov Disord. 2006;21:1618–1622.
60. Silberman C. D., Laks J, Capitao C. F., Rodrigues C. S., Moreira I, Engelhardt E. Recognizing depression in patients with Parkinson’s disease: accuracy and specificity of two depression rating scale. Arq Neuropsiquiatr. 2006;64:407–411.
61. Weintraub D, Oehlberg K. A., Katz I. R., Stern M. B. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry. 2006;14:169–175.
62. Yesavage J. A., Brink T. L., Rose T. L., et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1983;17:37–49.
63. Visser M, Leentjens A. F., Marinus J, Stiggelbout A. M., van Hilten J. J. Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease. Mov Disord. 2006;21:668–672.
64. Ertan T, Kiziltan G, Uygucgil H. Reliability and validity of the Geriatric Depression Scale in depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76:1445–1447.
65. Thompson A. W., Liu H, Hays R. D, et al. Diagnostic accuracy and agreement across three depression assessment measures for Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:40–45.
66. Chagas M. H., Tumas V, Rodrigues G. R., Machado-de-Sousa J. P, Filho A. S., Hallak. J.E, Crippa J. A. Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson’s disease. Age Ageing. 2013;42:645–649.
67. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology. 1981;31:645–650.
68. Starkstein S. E., Bolduc P. L., Mayberg H. S., et al. Cognitive impairments and depression in Parkinson’s disease: a follow up study. J Neurol Neurosurg Psychiatry. 1990;53:597–602.
69. Kuzis G, Sabe L, Tiberti C, Leiguarda R, Starkstein S. E. Cognitive functions in major depression and Parkinson disease. Arch Neurol. 1997;54:982–986.
70. Cubo E, Bernard B, Leurgans S, Raman R. Cognitive and motor function in patients with Parkinson’s disease with and without depression. Clin Neuropharmacol. 2000;23:331–334.
71. Anguenot A, Loll P. Y., Neau J. P., Ingrand P, Gil R. Depression and Parkinson’s disease: study of a series of 135 Parkinson’s patients can. J Neurol Sci. 2002;29:139–146.
72. Norman S, Troster A. I., Fields J. A., Brooks R. Effects of depression and Parkinson’s disease on cognitive functioning. J Neuropsychiatry Clin Neurosci. 2002;14:31–36.
73. Uekermann J, Daum I, Peters S, Wiebel B, Przuntek H, Müller T. Depressed mood and executive dysfunction in early Parkinson’s disease. Acta Neurol Scand. 2003;107:341–348.
74. Stefanova E, Potrebic A, Ziropadja L, Maric J, Ribaric I, Kostic V. S. Depression predicts the pattern of cognitive impairment in early Parkinson’s disease. J Neurol Sci. 2006;248:131–137.
75. Tröster A. I., Paolo A. M., Lyons K. E., Glatt S. L., Hubble J. P., Koller W. C. The influence of depression on cognition in Parkinson’s disease: a pattern of impairment distinguishable from Alzheimer’s disease. Neurology. 1995;45:672–676.
76. Tröster A. I., Stalp L. D., Paolo A. M., Fields J. A., Koller W. C. Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol. 1995;52:1164–1169.
77. Beliauskas L. A., Glantsz R. H. Depression type in Parkinson’s disease. J Clin Exp Neuropsychol. 1989;11:597–604.
78. Taylor A. E., Saint-Cyr J. A., Lang A. E., Kenny F. T. Parkinson’s disease and depression: a critical reevaluation. Brain. 1986;109:279–292.
79. Huber S. J., Paulson G. W., Shuttleworth E. C. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:855–858.
80. Silberman C. D., Laks J, Capitao C. F., et al. Frontal functions in depressed and nondepressed Parkinson’s disease patients: impact of severity stages. Psychiatry Res. 2007;149:285–289.
81. Santangelo G, Vitale C, Trojano L, Longo K, Cozzolino A, Grossi D, Barone P. Relationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia. J Neurol. 2009;256:632–638.
82. Varanese S, Perfetti B, Ghilardi M. F., Di Rocco A. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS ONE. 2011;6:e178–146.
83. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406.
84. Lemke M. R., Brecht H. M., Koester J, Kraus P. H., Reichmann H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17:214–220.
85. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B, Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601–607.
86. Rektorova I, Balaz M, Svatova J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson’s disease: a prospective multicenter study. Clin Neuropharmacol. 2008;31:261–266.
87. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–580.
88. Pahwa R, Stacy M. A., Factor S. A., Lyons K. E., Stocchi F, Hersh B. P., Elmer L. W., Truong D. D., Earl N. L., EASE-PD Adjunct Study Investigators. Ropinirole 24-h prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108–1115.
89. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90–99.
90. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010;10:49.
91. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42–80.
92. Richard I. H., McDermott M. P., Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229–1236.
93. Wermuth L, Sorensen P. S., Timm B, et al. Depression in idiopathic Parkinson’s disease treated with citalopram: a placebo-controlled trial. Nordic J Psychiatry. 1998;52:163–169.
94. Leentjens A. F., Vreeling F. W., Luijckx G. J., Verhey F. R. J. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2003;18:552–554.
95. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448–455.
96. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850–857.
97. Menza M, Dobkin R. D., Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72:886–892.
98. Dobkin R. D., Menza M, Allen L. A., et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168:1066–1074.
99. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Mov Disord. 2010;25:2311–2317.
100. Boggio P. S, Fregni F, Bermpohl F, et al. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson’s disease and concurrent depression. Mov Disord. 2005;20:1178–1184.
101. Fregni F, Santos C. M., Myczkowski M. L., et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:1171–1174.
102. Pedersen K. F., Larsen J. P., Alves G, Aarsland D. Prevalence and clinical correlates of apathy in Parkinson’s disease: a community-based study. Parkinsonism Relat Disord. 2009;15:295–299.
103. Starkstein S. E., Merello M, Jorge R, Brockman S, Bruce D, Power B. The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov Disord. 2009;24:1211–1216.
104. Drijgers R. L., Dujardin K, Reijnders J. S., Defebvre L, Leentjens A. F. Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Disord. 2010;16:656–660.
105. Duffy J. D. The neural substrates of motivation. Psychiatr Ann. 1997;27:24.
106. Reijnders J. S., Scholtissen B, Weber W. E., Aalten P, Verhey F. R., Leentjens A. F. Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxelbased morphometry. Mov Disord. 2010;25:2318–2325.
107. Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain. 2010;133(Pt 4):1111–1127.
108. Robert G, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Péron J, Travers D, Sauleau P, Millet B, Vérin M, Drapier D. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology. 2012;79:1155–1160.
109. Lhommèe E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, Fraix V, Xie J, AyaKombo M, Chabard’es S, Seigneuret E, Benabid A. L., Mertens P, Polo G, Carnicella S, Quesada J. L., Bosson J. L., Broussolle E, Pollak P, Krack P. Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain. 2012;135(Pt 5):1463–77.
110. Starkstein S. E. Apathy in Parkinson’s disease: diagnostic and etiological dilemmas. Mov Disord. 2012;27:174–178.
111. Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C. Apathy in Parkinson’s disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol. 2013;27:501–513.
112. Pedersen K. F., Alves G, Brønnick K, Aarsland D, Tysnes O. B., Larsen J. P. Apathy in drug-naïve patients with incident Parkinson’s disease: the Norwegian ParkWest study. J Neurol. 2010;257:217–223.
113. Pedersen K. F., Alves G, Aarsland D, Larsen J. P. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2009;80:1279–1282.
114. Cubo E, Benito-Leo’n J, Coronell C, Armesto D, ANIMO Study Group. Clinical correlates of apathy in patients recently diagnosed with Parkinson’s disease: the ANIMO study. Neuroepidemiology. 2012;38:48–55.
115. Harris E, McNamara P, Durso R. Apathy in patients with Parkinson disease as a function of side of onset. J Geriatr Psychiatry Neurol. 2013;26:95–104.
116. Marin R. S., Biedrzycki R. C., Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38:143–162.
117. Starkstein S. E., Mayberg H. S., Preziosi T. J., Andrezejewski P, Leiguarda R, Robinson R. G. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4:134–139.
118. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:579–584.
119. Robert P. H., Clairet S, Benoit M, et al. The apathy inventory: assessing apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17:1099–1105.
120. Cummings J. L., Mega M, Gray K, Rosenburg-Thompson S, Carusi D. A., Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314.
121. Fahn S, Elton RL, members of the UPDRS committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson’s disease. Florham Park: McMillan Health Care; 1987. p 153–163.
122. Leentjens A. F., Dujardin K, Marsh L, Martinez-Martin P, Richard I. H., Starkstein S. E., Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins G. T., Goetz C. G. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23:2004–2014.
123. Pluck G. C., Brown R. G. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:636–642.
124. Zahodne L. B., Young S, Kirsch-Darrow L, Nisenzon A, Fernandez H. H., Okun M. S., Bowers D. Examination of the Lille Apathy Rating Scale in Parkinson disease. Mov Disord. 2009;24:6776–83.
125. Santangelo G, Vitale C, Picillo M, Moccia M, Erro R, Pisano G, Pezzella D, Cuoco S, Longo K, Pellecchia M. T., Amboni M, De Rosa A, De Michele G, Trojano L, Barone P. Relationship between apathy and cognitive dysfunctions in de novo, untreated Parkinson’s Disease patients: a prospective longitudinal study. Eur J Neurol. 2014 May 22 [Epub ahead of print].
126. Dujardin K, Sockeel P, Delliaux M, Deste’e A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord. 2009;24:2391–2397.
127. I sella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord. 2002;17:366–371.
128. Zgaljardic D. J., Borod J. C., Foldi N. S., Rocco M, Mattis P. J., Gordon M. F., Feigin A. S., Eidelberg Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease. Cogn Behav Neurol. 2007;20:184–192.
129. Grossi D, Santangelo G, Barbarulo A. M., Vitale C, Castaldo G, Proto M. G., Siano P, Barone P, Trojano L. Apathy and related executive syndromes in dementia associated with Parkinson’s disease and in Alzheimer’s disease. Behav Neurol. 2013;27:515–522.
130. Santangelo G, Vitale C, Trojano L, Errico D, Amboni M, Barbarulo A. M., Grossi D, Barone P. Neuropsychological correlates of theory of mind in patients with early Parkinson’s disease. Mov Disord. 2012;27:98–105.
131. Czernecki V, Pillon B, Houeto J. L., Pochon J. B., Levy R, Dubois B. Motivation, reward, and Parkinson’s disease: influence of dopa therapy. Neuropsychologia. 2002;40:2257–2267.
132. Czernecki V, Schipbach M, Yaici S, Levy R, Bardinet E, Yelnik J, Dubois B, Agid Y. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23:964–969.
133. Leentjens A. F., Koester J, Fruh B, Shephard D. T., Barone P, Houben J. J. The effect of pramipex-ole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebocontrolled studies. Clin Ther. 2009;31:89–98.
134. Chaudhuri R. K., Martinez-Martin P, Antonini A, Brown R. G., Friedman J. H., Onofrj M, Surmann Ghys L, Trenkwalder C. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19:660–665.
135. Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada J. L., Bosson J. L., Pollak P, Broussolle E, Krack P. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136(Pt 5):1568–1577.
136. Litvinenko I. V., Odinak M. M., Mogil’naya V. I., Emelin A. Y. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol. 2008;38:937–945.
137. Grace J, Amick M. M., Friedman J. H. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80:18–23.
138. Stevens A, Peschk I, Schwarz J. Implicit learning, executive function and hedonic activity in chronic polydrug abusers, currently abstinent polydrug abusers and controls. Addiction. 2007;102:937–946.
139. Gard D. E, Kring A. M., Gard M. G., Horan W. P., Green M. F. Anhedonia in schizophrenia: distinct.ions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93:253–260.
140. Gard D, Germans Gard M, Kring A, John O. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J Res Pers. 2006;40:1086–1102.
141. Assogna F, Cravello L, Caltagirone C, Spalletta G. Anhedonia in Parkinson’s disease: a systematic review of the literature. Mov Disord. 2011;26:1825–1834.
142. Weintraub D, Cary M, Stern M, et al. Daily affect in Parkinson disease is responsive to life events and motor symptoms. Am J Geriatr Psychiatry. 2006;14:161–168.
143. Jordan L. L., Zahodne L. B., Okun M. S., Bowers D. Hedonic and behavioral deficits associated with apathy in Parkinson’s disease: potential treatment implications. Mov Disord. 2013;28:1301–1304.
144. Santangelo G, Morgante L, Savica R, et al. Anhedonia and cognitive impairment in Parkinson’s disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. Parkinsonism Relat Disord. 2009;15:576–581.
145. Reichmann H, Brecht M. H., Koster J, Kraus P. H., Lemke M. R. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs. 2003;17:965–973.
146. Isella V, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I, et al. Physical anhedonia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:1308–1311.
147. Lemke M. R., Brecht H. M., Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci. 2006;248:266–270.
148. Matsui K, Tachibana H, Yamanishi T, Oguru M, Toda K, Okuda B, Oka N. Clinical correlates of anhedonia in patients with Parkinson’s disease. Clin Neurol Neurosurg. 2013;115:2524–2527.
149. Nagayama H, Kubo S, Hatano T, Hamada S, Maeda T, Hasegawa T, Kadowaki T, et al. Validity and reliability assessment of a Japanese version of the Snaith-Hamilton pleasure scale. Intern Med. 2012;51:865–869.
150. Reichmann H, Odin P, Brecht H. M., Koster J, Kraus P. H. Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. J Neural Transm Suppl. 2006;71:17–25.
151. Kluger B. M., Krupp L. B., Enoka R. M. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology. 2013;80:409–416.
152. Fabbrini G, Latorre A, Suppa A, Bloise M, Frontoni M, Berardelli A. Fatigue in Parkinson’s disease: motor or non-motor symptom? Parkinsonism Relat Disord. 2013;19:148–452.
153. Brown R. G., Dittner A, Findley L, Wessely S. C. The Parkinson fatigue scale. Parkinsonism Relat Disord. 2005;11:49–55.
154. Berardelli A, Conte A, Fabbrini G, Bologna M, Latorre A, Rocchi L, Suppa A. Pathophysiology of pain and fatigue in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18 (S1):226–228.
155. Abe K, Takanashi M, Yanagihara T. Fatigue in patients with Parkinson’s disease. Behav Neurol. 2000;2:103–106.
156. Pavese N, Metta V, Bose S. K., Chaudhuri K. R., Brooks D. J. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain. 2010;133:3434–3443.
157. Lou J. S., Benice T, Kearns G, Sexton G, Nutt J. Levodopa normalizes exercise related cortico-motoneuron excitability abnormalities in Parkinson’s disease. Clin Neurophysiol. 2003;114:930–937.
158. Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurology. 1993;43:2016–2018.
159. Karlsen K, Larsen J. P., Tandberg E, Jørgensen K. Fatigue in patients with Parkinson’s disease. Mov Disord. 1999;14:237–241.
160. Herlofson K, Larsen J. P. The influence of fatigue on health-related quality oflife in patients with Parkinson’s disease. Acta Neurol Scand. 2003;107:1–6.
161. Alves G, Wentzel-Larsen T, Larsen J. P. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology. 2004;63:1908–1911.
162. Skorvanek M, Nagyova I, Rosenberger J, Krokavcova M, Ghorbani Saeedian R, Groothoff J. W., Gdovinova Z, van Dijk J. P. Clinical determinants of primary and secondary fatigue in patients with Parkinson’s disease. J Neurol. 2013;260:1554–1561.
163. Beiske A. G., Loge J. H., Hjermstad M. J., Svensson E. Fatigue in Parkinson’s disease: prevalence and associated factors. Mov Disord. 2010;25:2456–2460.
164. Hagell P, Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatr. 2009;80:489–492.
165. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, PRIAMO Study Group, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–1649.
166. Elbers R, van Wegen E. E., Rochester L, Hetherington V, Nieuwboer A, Willems A. M., et al. Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson’s disease? Mov Disord. 2009;24:1512–1518.
167. Friedman J, Brown R, Comella C, Garber C, Krupp L, Lou J, et al. Fatigue in Parkinson’s disease: a review. Mov Disord. 2007;22:297–308.
168. Falup-Pecurariu C. Fatigue assessment of Parkinson’s disease patient in clinic: specific versus holistic. J Neural Transm. 2013;120:577–581.
169. Friedman J. H., Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz C. G., Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010;25:805–822.
170. Krupp L. B., La Rocca N. G., Muir-Nash J, Steinberg A. D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123.
171. Yellen S. B., Cella D. F., Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63–74.
172. Smets E. M. A., Garseen B, Bonke B, Dehaes J. C. J. M. The multidimensional fatigue inventory (MFI). Psychometric properties of an instrument to assess fatigue. J Psychosom Res. 1995;39:315–325.
173. Hagell P, Ho'glund A, Reimer J, Eriksson B, Knutsson I, Widner H, Cella D. Measuring fatigue in Parkinson’s disease: a psychometric study of two brief generic fatigue questionnaires. J Pain Symptom Manage. 2006;32:420–432.
174. Grace J, Mendelsohn A, Friedman J. H. A comparison of fatigue measures in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:443–445.
175. Elbers R. G., Rietberg M. B., van Wegen E. E., Verhoef J, Kramer S. F., Terwee C. B., Kwakkel G. Self-report fatigue questionnaires in multiple sclerosis, Parkinson’s disease and stroke: a systematic review of measurement properties. Qual Life Res. 2012;21:925–944.
176. Elbers R. G., van Wegen E. E., Verhoef J, Kwakkel G. Reliability and structural validity of the Multidimensional Fatigue Inventory (MFI) in patients with idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:532–536.
177. Fisk J. D., Doble S. E. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002;11:263–272.
178. Martinez-Martin P, Catalan M. J., Benito-Leon J, Moreno A. O., Zamarbide I, Cubo E, van Blercon N, Arillo V. C., Pondal M, Linazasoro G, Alonso F, Ruiz P. G., Frades B. Impact of fatigue in Parkinson’s Disease: the fatigue impact scale for daily use (D-FIS). QualLife Res. 2006;15:597–606.
179. Schiehser D. M., Ayers C. R., Liu L, Lessig S, Song D. S., Filoteo J. V. Validation of the modified fatigue impact scale in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:335–338.
180. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol. 1992;49:305–307.
181. Havlikova E, Rosenberger J, Nagyova I, Middel B, Dubayova T, Gdovinova Z, et al. Clinical and psychosocial factors associated with fatigue in patients with Parkinson’s disease. arkinsonism Relat Disord. 2008;14:187–192.
182. Miwa H, Miwa T. Fatigue in patients with Parkinson’s disease: impact on quality of life. Intern Med. 2011;50:1553–1558.
183. Shulman L. M., Taback R. L., Bean J, Weiner W. J. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord. 2001;16:507–510.
184. Friedman J. H., Fernandez H. H. The nonmotor problems of Parkinson’s disease. Neurologist. 2000;6:8–27.
185. Nakamura T, Hirayama M, Hara T, Hama T, Watanabe H, Sobue G. Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson’s disease? Mov Disord. 2011;26:1869–1874.
186. Sáez-Francás N, Hernández-Vara J, Corominas-Roso M, Alegre J, Jacas C, Casas M. Relationship between poor decision-making process and fatigue perception in Parkinson’s disease patients. J Neurol Sci. 2014;337 (1–2):167–172.
187. Sáez-Francás N, Hernández-Vara J, Corominas Roso M, AlegreMartín J, CasasBrugué M. The association of apathy with central fatigue perception in patients with Parkinson’s disease. Behav Neurosci. 2013;127:237–244.
188. Havlikova E, Rosenberger J, Nagyova I, Middel B, Dubayova T, Gdovinova Z, et al. Impact of fatigue on quality of life in patients with Parkinson’s disease. Eur J Neurol. 2008;15:475–480.
189. Kang S. Y., Ma H. I., Lim Y. M., Hwang S. H., Kim Y. J. Fatigue in drug-naive Parkinson’s disease. Eur Neurol. 2013;70:59–64.
190. Lou J. S., Kearns G, Benice T, Oken B, Sexton G, Nutt J. Levodopa improves physical fatigue in Parkinson’s disease: a double-blind, placebo-controlled, crossover study. Mov Disord. 2003;18:1108–1114.
191. Abe K, Takanashi M, Yanagihara T, Sakoda S. Pergolide mesylate may improve fatigue in patients with Parkinson’s disease. Behav Neurol. 2001–2002;13:117–121.
192. Mendonça D. A., Menezes K, Jog M. S. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord. 2007;22:2070–2076.
193. Stocchi F, The ADAGIO Investigators. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. Eur J Neurol. 2014;21 (2):357–360.